Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  axitinib
Find trials that include:  Any drugs shown
Results 1-11 of 11 for your search:
Start Over
Adjuvant Axitinib Therapy of Renal Cell Cancer in High Risk Patients
Phase: Phase III
Type: Prevention
Age: 18 and over
Trial IDs: AP311736, NCI-2014-01024, NCT01599754
A Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients With Advanced or Metastatic Renal Cell Carcinoma
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 105RC101, NCI-2013-01264, NCT01806064
Antiandrogen Therapy with or without Axitinib before Surgery in Treating Patients with Previously Untreated Prostate Cancer with Known or Suspected Lymph Node Metastasis
Phase: Phase II
Type: Biomarker/Laboratory analysis, Tissue collection/Repository, Treatment
Age: 18 and over
Trial IDs: 2011-0231, NCI-2015-01711, NCI-2011-02749, NCT01409200
Study of Dalantercept and Axitinib in Patients With Advanced Renal Cell Carcinoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A041-04, NCI-2013-00667, ACE-041, NCT01727336
Axitinib in Treating Patients with Neurofibromatosis Type 2 or Progressive Vestibular Schwannomas
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: S14-00004, NCI-2014-01039, NCT02129647
Personalized Dose of Axitinib in Treating Patients with Previously Treated Local Recurrent or Metastatic Renal Cell Cancer
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: CASE7815, NCI-2016-00020, 15-1386, IRB# 15-1386, NCT02579811
A Phase 1b Study Of Axitinib In Combination With Crizotinib In Patients With Advanced Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A4061068, NCI-2014-00350, 2015-001724-31, NCT01999972
A Dose Finding Study To Evaluate Safety, Drug Interaction, Tumor Markers Of Axitinib In Combination With MK-3475 In Adult Patients With Previously Untreated Advanced Renal Cell Cancer
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: A4061079, NCI-2014-01997, NCT02133742
Axitinib in Treating Younger Patients with Recurrent or Refractory Solid Tumors
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 1 to 17
Trial IDs: ADVL1315, NCI-2014-01093, NCT02164838
A Study Of Avelumab In Combination With Axitinib In Advanced Renal Cell Cancer (JAVELIN Renal 100)
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: B9991002, NCI-2016-00044, 2015-001137-25, Javelin Renal 100, NCT02493751
Axitinib and L-Selenomethionine in Treating Patients with Previously Treated Advanced Metastatic Clear Cell Renal Cell Carcinoma
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 201507716, NCI-2015-02235, NCT02535533
Start Over